NCT07075757View on ClinicalTrials.gov

In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

November 1, 2028

Study Completion Date

November 1, 2028

Conditions
Brain Arteriovenous Malformations
Interventions
DRUG

Single in situ intra-arterial injection of bevacizumab

3 Escalating doses of an in situ intra-arterial injection of Bevacizumab (5 mg/kg, 7.5 mg/kg, 10 mg/kg)

Trial Locations (5)

54000

CHU de Nancy, Hôpital Central, Nancy

75013

APHP, Hôpital Pitié-Salpêtrière, Paris

75014

Centre Hospitalier Sainte-Anne, Paris

76000

CHU de Rouen, Hôpital Charles-Nicolle, Rouen

87000

CHU de Limoges, Hôpital Dupuytren, Limoges

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER